

# $\begin{array}{l} \text{FFR}_{\text{CT}} \\ \text{The Basics} \end{array}$

Campbell Rogers MD, FACC Chief Medical Officer HeartFlow, Inc.



## Diagnosing anatomic and functionally-significant CAD



Cardiac CT has emerged as a superb noninvasive method for imaging coronary anatomy, but does not provide functional data



Images provided by J. Leipsic

## Coronary CT angiography

- Coronary CTA has a high sensitivity and high negative predictive value for diagnosis of obstructive CAD
- However, coronary CTA cannot define the hemodynamic significance of coronary lesions



>50% diameter stenosis



>50% diameter stenosis

# Obstructive CAD identified by coronary CTA or by Coronary Angiography correlates poorly with FFR

>50% of lesions with greater than 50% diameter stenosis by CCTA have FFR> $0.8^{1}$ 



65% of intermediate lesions are incorrectly identified for stent placement by Angiograms<sup>2</sup>



Stenosis classification by angiography

Meijboom et al. J Am CollCardiol 2008;52:636–43
 Tonino et al. JACC 2010;55:2816-21

# Diagnostic performance of Coronary diagnostic tests for Functional (FFR $\leq$ 0.80) disease



## Diagnosing anatomic and functionally-significant CAD





## **FFR<sub>CT</sub> Technology**



#### Patient-Specific Coronary Flow and Pressure:

- Using a standard CT dataset a quantitative model is built
- A physiological model is developed using LV and coronary anatomy and established form-function principles
- A fluid model calculates flow and pressure under simulated hyperemic conditions

Taylor et al, JACC 2013; 61: 2233-41

## FFR<sub>CT</sub> Analysis Process



#### Heart Flow<sup>-</sup>

#### FFR<sub>CT</sub> Results





Measured Fractional Flow Reserve (FFR) values ≤ 0.80 suggest hemodynamic (functional) significance (1,2,3).





Created with FFR<sub>ct</sub> HeartFlow\_v1.5.0.823 on 1/22/2014 10:44:24 PM UTC. HFID: 3aa905ef-4f87-4cde-9f3a-d8ecab6ee7f2 Copyright 2013 HeartFlow, Inc. All rights reserved. FFR<sub>ct</sub>, HeartFlow and the HeartFlow logo are among the trademarks of HeartFlow, Inc. 1400 Seaport Blvd • Building B • Redwood City, CA 94063 USA • tel: +1.650.241.1221 • fax: +1.650.368.2564 • www.heartflow.com

page 1 of 3



**Right Coronary Artery System** 

#### $\mathsf{FFR}_{\mathsf{CT}}\,\mathsf{Results}$



Measured Fractional Flow Reserve (FFR) values < 0.80 suggest hemodynamic (functional) significance (1,2,3).

0.94

RCA



Created with FFR<sub>CT</sub> HeartFlow\_v1.5.0.823 on 1/15/2014 2:17:44 AM UTC. HFID: 3b5e974c-48f7-4cd6-82d3-d7bad4c1d582 Copyright 2013 HeartFlow, Inc. All rights reserved. FFR<sub>CT</sub>, HeartFlow and the HeartFlow logo are among the trademarks of HeartFlow, Inc. 1400 Seaport Blvd • Building B • Redwood City, CA 94063 USA • tel: +1.650.241.1221 • fax: +1.650.368.2564 • www.heartflow.com

## $FFR_{CT}$ Analysis Process



## Physiological Boundary Conditions: Resting Coronary Flow

## Scientific Principle #1:

## Resting coronary blood flow proportional to myocardial mass



Measuring the size of the organ to determine total coronary flow

## Physiological Boundary Conditions: Coronary Microcirculatory Resistance

#### Scientific Principle #2

Resistance of microcirculatory vascular bed at rest is inversely proportional to size of feeding vessel

HeartFlow technology leverages 30 years of research on hemodynamics, vascular wall biology and atherosclerosis

#### COMPENSATORY ENLARGEMENT OF HUMAN ATHEROSCLEROTIC CORONARY ARTERIES

Seymour Glagov, M.D., Elliot Weisenberg, B.A., Christopher K. Zarins, M.D., Regina Stankunavicius, M.P.H., and George J. Kolettis, B.A.



- Atherosclerotic plague evolution
- Artery wall adaptive responses

•

#### The ability to calculate microcirculatory resistance

Small coronary artery branches have a higher resistance to flow than larger branches

## Physiological Boundary Conditions: Effect of Adenosine

## Scientific Principle #3

Microcirculation has a predictable response to adenosine



Adenosine relaxes smooth muscle cells lining arterioles resulting in vasodilation



Intravenous administration of adenosine elicits remarkably consistent vasodilatory response at sufficient doses

#### The ability to model the effect of adenosine

## HeartFlow Clinical Trial Data

#### DISCOVER-FLOW

- Completed 2011
- N=104 patients

# Image: Constraint of the strength of the strengt of the strength of the strength of the strength of the

#### DeFACTO

- Completed 2012
- N=252 patients

#### ONLINE FIRST

#### Diagnostic Accuracy of Fractional Flow Reserve From Anatomic CT Angiography

JAMA. 2012;308(12):doi:10.1001/2012.jama.11274

## • NXT

- Completed 2013
- N=254 patients
- 10 Worldwide Sites
  - EU
  - Australia
  - Japan
  - Korea



## **HeartFlow Clinical Trial Case Examples**



### Estimated Patient Radiation Exposure Based on CAD Dx Pathway



# What are the health economic tradeoffs associated with FFR use in patients with known CAD?





#### Clinical Investigations

#### Projected Costs and Consequences of Computed Tomography-Determined Fractional Flow Reserve

Mark A . Hlatky, MD; Akshay Saxena, MD; Bon-Kwon Koo, MD; Andrejs Erglis, MD; Christopher K. Zarins, MD; James K. Min, MD

	Diagnostic Strategy		
	ICA/Visual	ICA/FFRICA	cCTA/ICA/Visual
No. of ICAs (per 100 patients)	100	100	84
No. of patients undergoing PCI (per 100 patients)	81	48	72
No. of vessels treated by PCI (per 100 patients)	98	51	88
No. of vessels treated per patient undergoing PCI	1.21	1.07	1.22
Death/MI rate at 1 year	2.63%	1.96%	2.56%
Initial treatment costsper patient	\$10702	\$8499	\$9635

Hlatky et al, Clin Cardiol 2013; DOI:10.1002/clc.22205 © 2013 Wiley Periodicals, Inc.



#### **Clinical** Investigations

#### Projected Costs and Consequences of Computed Tomography-Determined Fractional Flow Reserve

Mark A . Hlatky, MD; Akshay Saxena, MD; Bon-Kwon Koo, MD; Andrejs Erglis, MD; Christopher K. Zarins, MD; James K. Min, MD

	Diagnostic St			
	ICA/Visual	ICA/FFRICA	cCTA/ICA/Visual	cCTA/FFR <sub>CT</sub> /ICA
No. of ICAs (per 100 patients)	100	100	84	51
No. of patients undergoing PCI (per 100 patients)	81	48	72	49
No. of vessels treated by PCI (per 100 patients)	98	51	88	59
No. of vessels treated per patient undergoing PCI	1.21	1.07	1.22	1.21
Death/MI rate at 1 year	2.63%	1.96%	2.56%	2.31%
Initial treatment costsper patient	\$10702	\$8499	\$9635	\$7674

 Use of FFR<sub>CT</sub> to select patients for ICA and PCI may result in 30% lower costs and 12% fewer events at one year compared to the most common strategy of ICA and visual guidance for PCI

Hlatky et al, Clin Cardiol 2013; DOI:10.1002/clc.22205 © 2013 Wiley Periodicals, Inc.

## **Primary Peer-reviewed Publications**

1.	DISCOVER-FLOW study results	Коо	JACC 2011; 58: 1989
2.	DISCOVER-FLOW intermediate stenosis	Min	Am J Cardiol 2012; 971
3.	DISCOVER-FLOW image quality	Min	JCCT 2012; 6: 191
4.	DeFACTO rationale and design	Min	JCCT 2011; 5: 3011
5.	DeFACTO study results	Min	JAMA 2012; 308(12): 1237
6.	DeFACTO intermediate stenosis	Nakazato	Circulation: CV Imaging 2013 ; 6: 881
7.	DeFACTO image quality, patient prep	Leipsic	Am J Radiology 2013, in press
8.	Non-invasive FFR: scientific basis	Serruys	EuroIntervention 2012; 8: 511
9.	Scientific basis of FFR <sub>CT</sub>	Taylor	JACC 2013, 61: 2233-41
10.	FFR <sub>ct</sub> derived from cCTA	Zarins	J Cardiovasc Transl Res 2013
11.	Non-inv dx of ischemia-causing stenosis	Yoon	JACC Imaging 2012; 5: 1088
12.	CT-FFR next level in cardiac imaging	Meijs	Neth Heart J 2012; 20: 410
13.	Noninvasive FFR using CT	Yoon	Cardiovasc Dx and Rx 2012; 2: 105
14.	Integrating physiology and anatomy	Arsanjani	Curr Cardiovasc Imaging Rep 2012; 5: 301
1			
15.	Modeling of FFR based on cCTA	Grunau	Curr Cardio Rep 2013; 15: 336
15. 16.	Modeling of FFR based on cCTA ABSORB trial 5 year follow up	Grunau Serruys	Curr Cardio Rep 2013; 15: 336 JACC Interventions 2013, 6: 999
15. 16. 17.	Modeling of FFR based on cCTA ABSORB trial 5 year follow up FFR <sub>cT</sub> anatomic-functional integration	Grunau Serruys Al-Hassan	Curr Cardio Rep 2013; 15: 336 JACC Interventions 2013, 6: 999 Future Cardiol 2013; 9: 243
15. 16. 17. 18.	Modeling of FFR based on cCTA ABSORB trial 5 year follow up FFR <sub>cT</sub> anatomic-functional integration New frontiers in CTA	Grunau Serruys Al-Hassan Min	Curr Cardio Rep 2013; 15: 336 JACC Interventions 2013, 6: 999 Future Cardiol 2013; 9: 243 Heart 2013; 99: 661
15. 16. 17. 18. 19.	Modeling of FFR based on cCTA ABSORB trial 5 year follow up FFR <sub>CT</sub> anatomic-functional integration New frontiers in CTA Virtual FFR by CT	Grunau Serruys Al-Hassan Min Rajani	Curr Cardio Rep 2013; 15: 336 JACC Interventions 2013, 6: 999 Future Cardiol 2013; 9: 243 Heart 2013; 99: 661 Eurointervention 2013; 9:277
<ol> <li>15.</li> <li>16.</li> <li>17.</li> <li>18.</li> <li>19.</li> <li>20.</li> </ol>	Modeling of FFR based on cCTA ABSORB trial 5 year follow up FFR <sub>cT</sub> anatomic-functional integration New frontiers in CTA Virtual FFR by CT Physiologic assessment of CAD by CT	Grunau Serruys Al-Hassan Min Rajani Kochar	Curr Cardio Rep 2013; 15: 336 JACC Interventions 2013, 6: 999 Future Cardiol 2013; 9: 243 Heart 2013; 99: 661 Eurointervention 2013; 9:277 Korean Circ J 2013; 43: 435
<ol> <li>15.</li> <li>16.</li> <li>17.</li> <li>18.</li> <li>19.</li> <li>20.</li> <li>21.</li> </ol>	Modeling of FFR based on cCTA ABSORB trial 5 year follow up FFR <sub>cT</sub> anatomic-functional integration New frontiers in CTA Virtual FFR by CT Physiologic assessment of CAD by CT Virtual coronary stenting and FFR <sub>cT</sub>	Grunau Serruys Al-Hassan Min Rajani Kochar Kim	Curr Cardio Rep 2013; 15: 336 JACC Interventions 2013, 6: 999 Future Cardiol 2013; 9: 243 Heart 2013; 99: 661 Eurointervention 2013; 9:277 Korean Circ J 2013; 43: 435 JACC Interventions 2013
<ol> <li>15.</li> <li>16.</li> <li>17.</li> <li>18.</li> <li>19.</li> <li>20.</li> <li>21.</li> <li>22.</li> </ol>	Modeling of FFR based on cCTA ABSORB trial 5 year follow up FFR <sub>cT</sub> anatomic-functional integration New frontiers in CTA Virtual FFR by CT Physiologic assessment of CAD by CT Virtual coronary stenting and FFR <sub>cT</sub> Cost-consequences of FFR <sub>cT</sub>	Grunau Serruys Al-Hassan Min Rajani Kochar Kim Hlatky	Curr Cardio Rep 2013; 15: 336 JACC Interventions 2013, 6: 999 Future Cardiol 2013; 9: 243 Heart 2013; 99: 661 Eurointervention 2013; 9:277 Korean Circ J 2013; 43: 435 JACC Interventions 2013 Clinical Cardiology 2013, 36: 743
<ol> <li>15.</li> <li>16.</li> <li>17.</li> <li>18.</li> <li>19.</li> <li>20.</li> <li>21.</li> <li>22.</li> <li>23.</li> </ol>	Modeling of FFR based on cCTA ABSORB trial 5 year follow up FFR <sub>cT</sub> anatomic-functional integration New frontiers in CTA Virtual FFR by CT Physiologic assessment of CAD by CT Virtual coronary stenting and FFR <sub>cT</sub> Cost-consequences of FFR <sub>cT</sub> HeartFlowNXT rationale and design	Grunau Serruys Al-Hassan Min Rajani Kochar Kim Hlatky Gaur	Curr Cardio Rep 2013; 15: 336 JACC Interventions 2013, 6: 999 Future Cardiol 2013; 9: 243 Heart 2013; 99: 661 Eurointervention 2013; 9:277 Korean Circ J 2013; 43: 435 JACC Interventions 2013 Clinical Cardiology 2013, 36: 743 JCCT 2013, 7: 279